Initiation Archives - Page 268 of 272

1 minute read

Capital One Initiates Coverage On American Homes 4 Rent with Overweight Rating, Announces Price Target of $43

July 8, 9:31 AM

Capital One analyst Chris Lucas initiates coverage on American Homes 4 Rent (NYSE:AMH) with a Overweight rating and announces Price Target of $43.

AMH

1 minute read

Northland Capital Markets Initiates Coverage On Bloom Energy with Outperform Rating, Announces Price Target of $28

By Benzinga Newsdesk

July 8, 9:14 AM

Northland Capital Markets analyst Donovan Schafer initiates coverage on Bloom Energy (NYSE:BE) with a Outperform rating and announces Price Target of $28.

1 minute read

Jefferies Initiates Coverage On CCC Intelligent Solutions with Buy Rating, Announces Price Target of $12

By Benzinga Newsdesk

July 8, 9:07 AM

Jefferies analyst David Kelley initiates coverage on CCC Intelligent Solutions (NYSE:CCCS) with a Buy rating and announces Price Target of $12.

CCCS

1 minute read

Benchmark Initiates Coverage On DPCM Capital with Buy Rating, Announces Price Target of $14

By Benzinga Newsdesk

July 8, 6:15 AM

Benchmark analyst David Williams initiates coverage on DPCM Capital (NYSE:XPOA) with a Buy rating and announces Price Target of $14.

XPOA

1 minute read

Chardan Capital Initiates Coverage On Immuneering with Buy Rating, Announces Price Target of $18

By Benzinga Newsdesk

July 8, 6:08 AM

Chardan Capital analyst Geulah Livshits initiates coverage on Immuneering (NASDAQ:IMRX) with a Buy rating and announces Price Target of $18.

IMRX

1 minute read

Benchmark Initiates Coverage On NOW with Buy Rating, Announces Price Target of $13

By Benzinga Newsdesk

July 8, 5:01 AM

Benchmark analyst Douglas Becker initiates coverage on NOW (NYSE:DNOW) with a Buy rating and announces Price Target of $13.

DNOW

1 minute read

Oppenheimer Initiates Coverage On Blueprint Medicines with Outperform Rating, Announces Price Target of $80

By Benzinga Newsdesk

July 8, 4:59 AM

Oppenheimer analyst Matthew Biegler initiates coverage on Blueprint Medicines (NASDAQ:BPMC) with a Outperform rating and announces Price Target of $80.

BPMC